Brydg Secures CBILS Accreditation to Provide Relief to Real Estate Businesses
Government-Backed Loans of £250,000 to £5 Million available to support recovery for eligible small businesses in the UK
LONDON, Jan. 13, 2021 /PRNewswire/ Brydg today announced that it has been accredited as a new lender for the Coronavirus Business Interruption Loan Scheme (CBILS) by the British Business Bank.
Delivered through British Business Bank accredited lenders, CBILS is designed to support the continued provision of finance to UK smaller businesses (SMEs) during the Covid-19 outbreak. The scheme enables lenders to provide facilities of up to £5m to smaller businesses across the UK who are experiencing lost or deferred revenues, leading to disruptions to their cashflow.
Boehringer Ingelheim receives EMA marketing authorization for NexGard COMBO, the first isoxazoline-based full endectocide for cats
This innovative broad spectrum topical parasiticide is easy and convenient for cat owners.
It kills a wider range of parasites than any other product on the market, covering core external parasites like fleas and ticks as well as internal parasites, including tapeworms.
Boehringer Ingelheim, a global leader in animal health, is proud to announce that it has received marketing authorization from the EMA (European Medicine Agency) and European Commission for its NexGard COMBO topical solution for cats. This innovative parasiticide will be available in the European Union shortly. NexGard
KENDALLVILLE — CARF International announced that Northeastern Center, Inc. has been accredited for a period of three years for its crisis intervention, inpatient, crisis stabilization, community housing, community integration, outpatient
CN Bio s PhysioMimix Technology Receives FDA Recognition
Represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator
CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA)
1. The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bio s proprietary PhysioMimix system is appropriate for use in drug safety and metabolism applications, evidencing its enhanced performance versus standard techniques. The publication substantiates the Company s position as a leader in the field with reliable and robust cutting-edge technology, ready for widespread adoption across the pharmaceutical industry.